Oculis Holding AG (OCS) Competitors & Peers
The 5 largest companies in the same industry as Oculis Holding AG, by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| VRTX | Peer | $526.19 | P/E 30.2RSI 51Cap 133.4 B |
| REGN | Competitor | $788.04 | P/E 19.5RSI 48Cap 81.1 B |
| ARGX | Peer | $959.49 | P/E 36.5RSI 45Cap 60.0 B |
| RVMD | Peer | $204.97 | RSI 41Cap 41.4 B |
| ALNY | Peer | $255.96 | P/E 44.6RSI 56Cap 34.2 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- LZAGYSupplier
Lonza serves as a CDMO supplier, manufacturing clinical-grade drug candidates and nanoparticle eye drop formulations.
Model-inferred, unverified — treat as a lead, not evidence - ACCUREPartner
Oculis in-licensed OCS-05/Privosegtor from Accure to expand its neuroprotective drug pipeline.
Model-inferred, unverified — treat as a lead, not evidence - NVSPartner
Oculis in-licensed OCS-02 (licofelanem) TNF-alpha antibody droplet tech from Novartis.
Model-inferred, unverified — treat as a lead, not evidence - REGNCompetitor
Competes in DME treatments; OCS-01 aims to replace Regeneron's Eylea (eye injection) with a topical eye drop.
Model-inferred, unverified — treat as a lead, not evidence - ALCCompetitor
Competes in global ophthalmic therapeutic solutions and dry-eye droplet segments.
Model-inferred, unverified — treat as a lead, not evidence